Ken Griffin Axsome Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$65.72 - $80.5 $335,172 - $410,550	5,100 Added 6.68%	81,500 $6.56 Million
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $2.39 Million - $3.37 Million	-34,500 Reduced 31.11%	76,400 $6.1 Million
Q4 2023 Feb 14, 2024	BUY	$57.42 - $83.61 $1.68 Million - $2.44 Million	29,200 Added 35.74%	110,900 $8.83 Million
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $11.5 Million - $13.7 Million	-166,300 Reduced 67.06%	81,700 $5.71 Million
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $5.44 Million - $8.42 Million	93,200 Added 60.21%	248,000 $17.8 Million
Q1 2023 May 15, 2023	SELL	$58.39 - $75.0 $19.2 Million - $24.7 Million	-329,600 Reduced 68.04%	154,800 $9.55 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $4.72 Million - $9.41 Million	-118,100 Reduced 19.6%	484,400 $37.4 Million
Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $169,482 - $328,295	-4,700 Reduced 0.77%	602,500 $26.9 Million

296

40.4M

365K

423K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.86B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.